title: Control of carcinoid syndrome with everolimus.
authors.affiliation: Medical Oncology Service. Electronic address: jacapdevila@vhebron.net.
authors.forename: J
authors.initials: J
authors.lastname: Capdevila
authors.affiliation: Interventionist Radiology Service.
authors.forename: I
authors.initials: I
authors.lastname: Díez Miranda
authors.affiliation: Endocrinology Service, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Obiols
authors.affiliation: Medical Oncology Service.
authors.forename: J
authors.initials: J
authors.lastname: Tabernero
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy; D000068338:Everolimus; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage; D011994:Recombinant Proteins; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068338:Everolimus; D015282:Octreotide; D020123:Sirolimus